Aldesleukin
- Generic Name
- Aldesleukin
- Brand Names
- Proleukin
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 110942-02-4
- Unique Ingredient Identifier
- M89N0Q7EQR
- Background
Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This recombinant form differs from native interleukin-2 in the following ways: a) Aldesleukin is not glycosylated because it is derived from E. coli; b) the molecule has no N-terminal alanine; the codon for this amino acid was deleted during the genetic engineering procedure; c) the molecule has serine substituted for cysteine at amino acid position 125.
- Indication
For treatment of adults with metastatic renal cell carcinoma.
- Associated Conditions
- Metastatic Melanoma, Metastatic Renal Cell Carcinoma ( mRCC)
- Associated Therapies
- -
Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer
- Conditions
- Metastatic MelanomaMetastatic Renal Cancer
- Interventions
- First Posted Date
- 2010-07-12
- Last Posted Date
- 2015-10-28
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 9
- Registration Number
- NCT01160445
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Phase 1/2 Study of Metastatic Renal Cancer Using T-Cells Transduced With a T-Cell Receptor Which Recognizes TRAIL Bound to the DR4 Receptor
- Conditions
- Renal CancerKidney Cancer
- First Posted Date
- 2009-06-18
- Last Posted Date
- 2019-04-09
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 5
- Registration Number
- NCT00923390
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Chemotherapy Followed by Infusion of DMF5 Cells to Treat Metastatic Melanoma
- Conditions
- MelanomaMalignant MelanomaMelanoma, Experimental
- Interventions
- First Posted Date
- 2009-06-18
- Last Posted Date
- 2012-10-25
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 1
- Registration Number
- NCT00924001
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma
- Conditions
- Diffuse, Large B-cell LymphomaMantle CellPrimary Mediastinal B-cell LymphomaDiffuse Large B-Cell Lymphoma Transformed From Follicular Lymphoma
- Interventions
- Biological: Anti-cluster of differentiation 19 (CD19)-CAR PBLDrug: FludarabineDrug: CyclophosphamideDrug: Aldesleukin
- First Posted Date
- 2009-06-18
- Last Posted Date
- 2022-01-12
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 43
- Registration Number
- NCT00924326
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma
- Conditions
- Skin CancerMelanoma
- Interventions
- Drug: Montanide ISA 51 VGProcedure: RadiationDrug: AldesleukinDrug: FludarabineDrug: CyclophosphamideGenetic: Anti-MART-1 F5 TCR PBL
- First Posted Date
- 2009-06-18
- Last Posted Date
- 2015-10-28
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 4
- Registration Number
- NCT00923195
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Gene Therapy Using Anti-CEA Cells to Treat Metastatic Cancer
- Conditions
- Metastatic Cancer
- Interventions
- Biological: PG13-CEA_TCR (Anti-CEA TCR PBL)Drug: Aldesleukin
- First Posted Date
- 2009-06-18
- Last Posted Date
- 2015-10-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 3
- Registration Number
- NCT00923806
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer
- Conditions
- Metastatic Renal Cell CancerMetastatic CancerMetastatic Melanoma
- Interventions
- Biological: Anti-NY ESO-1 T-cell receptor PBLDrug: aldesleukinDrug: CyclophosphamideDrug: fludarabine phosphateBiological: ALVAC NY ESO-1 vaccine
- First Posted Date
- 2008-05-02
- Last Posted Date
- 2019-11-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 45
- Registration Number
- NCT00670748
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Chemotherapy Followed by gp100 Lymphocytes and Aldesleukin to Treat Melanoma
- First Posted Date
- 2008-04-24
- Last Posted Date
- 2015-10-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 10
- Registration Number
- NCT00665470
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Treating Patients With Childhood Acute Myeloid Leukemia With Interleukin-2
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2009-02-12
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 580
- Registration Number
- NCT00149162
- Locations
- 🇫🇷
Children Armand Trousseau Hospital, Paris, France
Safety and Effectiveness of Immunotherapy With Autologous HIV-Specific CD8 Cells in HIV Infected Adults
- Conditions
- HIV Infections
- First Posted Date
- 2005-05-11
- Last Posted Date
- 2008-08-08
- Target Recruit Count
- 24
- Registration Number
- NCT00110578
- Locations
- 🇺🇸
University of Washington (UW), Seattle, Washington, United States
🇺🇸Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.